Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CAR.5/IL15-transduced CB-NK cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on CAR.5/IL15-transduced CB-NK cells (Mar 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CAR.5/IL15-transduced CB-NK cells | Limited information is currently available on CAR.5/IL15-transduced CB-NK cells (Mar 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Active, not recruiting | USA | 0 |